Third Point – Danaher: Don’t Be Surprised If Growth Rate Moves To Low Teens

Summary:

  • Danaher has underperformed the S&P 500 this year due to a slowdown in the bioprocessing industry and cautious spending by biopharma customers.
  • The bioprocessing industry is expected to return to normalized growth in 2024 and beyond.
  • Danaher is set to spin-off its Environmental & Applied Solutions division in Q4 of this year, becoming a pure-play life sciences tools and diagnostics company.

Digital network connection. Abstract connection of dots and lines. Technology background. Plexus effect. 3d rendering.

Olga Tsyvinska

The following segment was excerpted from this fund letter.


Equity Position Update: Danaher (NYSE:DHR)

Danaher is our longest held investment and remains a top five position.

Danaher has underperformed the S&P 500 (SP500, SPX) this

Leave a Reply

Your email address will not be published. Required fields are marked *